IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024

Aggregated presentation by day and by market

Purchases of own shares from June 17th to 21th  2024
       
Name of the IssuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)
IPSEN549300M6SGDPB4Z94P1117/06/2024FR00102591506 600120,3723XPAR
IPSEN549300M6SGDPB4Z94P1117/06/2024FR00102591502 400120,4326CEUX
IPSEN549300M6SGDPB4Z94P1117/06/2024FR0010259150515120,4006TQEX
IPSEN549300M6SGDPB4Z94P1117/06/2024FR0010259150485120,4344AQEU
IPSEN549300M6SGDPB4Z94P1118/06/2024FR00102591507 537119,3154XPAR
IPSEN549300M6SGDPB4Z94P1118/06/2024FR00102591502 463119,0330CEUX
IPSEN549300M6SGDPB4Z94P1119/06/2024FR00102591504 000117,7254XPAR
IPSEN549300M6SGDPB4Z94P1120/06/2024FR00102591505 743117,1677XPAR
IPSEN549300M6SGDPB4Z94P1120/06/2024FR00102591501 957117,1431CEUX
IPSEN549300M6SGDPB4Z94P1120/06/2024FR0010259150100117,0000TQEX
IPSEN549300M6SGDPB4Z94P1120/06/2024FR0010259150200116,9350AQEU
IPSEN549300M6SGDPB4Z94P1121/06/2024FR00102591502 737115,3567XPAR
IPSEN549300M6SGDPB4Z94P1121/06/2024FR00102591501 263115,0259CEUX
   TOTAL36 000 118,4864 

Attachment



EN
25/06/2024

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholesta...

Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease                                                                  Kayfanda® (odevixibat) approved as new treatment choice for cholestatic pruritus in children from six months with the rare liver condition, Alagille Syndrome E.U. marketing authorization for Kayfanda based on data from ASSERT the only Phase III trial completed in patients with Alagille SyndromeKayfanda approval for use in the E.U. further expands Ipsen’s rare cholestatic liver disease portfolio ...

September 23, 2024 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Le médicament Kayfanda® (odévixibat) d’Ipsen est approuvé dans l’Union...

Le médicament Kayfanda® (odévixibat) d’Ipsen est approuvé dans l’Union européenne pour le prurit cholestatique lié au syndrome d’Alagille, une maladie hépatique rare                                                                          Kayfanda® (odévixibat) a été approuvé comme nouvelle option thérapeutique pour le prurit cholestatique chez l’enfant de six mois ou plus atteint du syndrome d’Alagille, une maladie rare du foie. L’autorisation de mise sur le marché accordée dans l’UE pour Kayfanda se base sur les données d’ASSERT, le seul essai de Phase III mené à son terme chez des pa...

September 23, 2024 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first ...

Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows positive CHMP opinion based on ELATIVE phase III trial data, which demonstrated significant efficacy over placebo and was well-tolerated with an acceptable safety profile This new European approval reinforces Ipsen’s commitment to advancing medical innovations to tre...

September 20, 2024 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Le médicament Iqirvo® (élafibranor) d’Ipsen est approuvé dans l’Union ...

Le médicament Iqirvo® (élafibranor) d’Ipsen est approuvé dans l’Union européenne comme premier nouveau traitement contre la cholangite biliaire primitive depuis près d’une décennie    La Commission européenne accorde une autorisation de mise sur le marché conditionnelle à Iqirvo® (élafibranor), nouveau traitement premier de sa classe thérapeutique contre la cholangite biliaire primitive (CBP), une maladie rare du foie.L’approbation fait suite à l’avis positif rendu par le CHMP sur la base des données de l’essai de Phase III ELATIVE, qui ont démontré une efficacité significative par rapport...

September 20, 2024 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Final results from CABINET Phase III trial reinforce efficacy benefits...

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx® (cabozantinib) versus placebo in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs)1,2Data presented at ESMO 2024 and published in New England Journal of Medicine Ipsen has submitted an extension of indication Marketing Authorization to the European Medicines AgencyLimited approved treatment options for advanced NETs depe...

September 16, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch